The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Antibody Contract Manufacturing Market, 2020 - 2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    January 2020

  • Pages
    305

  • View Count
    5523

Example Insights

	Antibody Contract Manufacturing Market, 2019-2030 -Context Antibody Contract Manufacturing Market, 2019-2030 -Example Highlight 	Antibody Contract Manufacturing Market, 2019-2030-Market Landscape
Antibody Contract Manufacturing Market, 2019-2030 -Partnerships & Collaborations Antibody Contract Manufacturing Market, 2019-2030 -Capacity Analysis Antibody Contract Manufacturing Market, 2019-2030 -Recent Expansions
Antibody Contract Manufacturing Market, 2019-2030 -Benchmark Analysis Antibody Contract Manufacturing Market, 2019-2030 -Demand & Supply analysis 	Antibody Contract Manufacturing Market, 2019-2030 -Futuer Forecast

 

Overview

Since the approval of Orthoclone OKT3® in 1986, monoclonal antibodies have become an important part of modern healthcare practices. In fact, several experts consider monoclonal antibodies to be the backbone of the biopharmaceutical industry. It is worth noting that, till date, more than 100 therapeutic monoclonal antibodies have been approved across different geographies; recent approvals include (in reverse chronological order) Adakveo® (November 2019), Beovu® (October 2019), SKYRIZI™ (April 2019) and EVENITY™ (April 2019). Owing to their high specificity and the favorable safety profile associated with the therapeutic use of such molecules, antibody based interventions presently constitute the largest class of biologics in the industry. This trend is unlikely to change in the near future as advanced variants, such as bispecific antibodies and antibody fragments-based products, are steadily gaining traction. Further, owing to legacy challenges associated with the development and production of biologics, such as advanced supply chain requirements, outsourcing antibody production operations is a popular trend. 

The antibody contract manufacturing market is highly competitive, featuring companies of all sizes, some of which claim to offer end-to-end solutions, ranging from antibody development to commercial production. Historical and prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing. This dependence on outsourcing can be attributed to the high cost and time investment required to establish the necessary infrastructure and expertise in biologics. The competition among contract manufacturing organizations (CMOs) engaged in this domain is high, with the availability of cutting-edge tools and technologies being one of the key differentiating factors that grant a competitive advantage over other players. Therefore, in order to establish a strong foothold in the market and also meet the growing demand for antibody therapeutics / reagents, CMOs are actively expanding their capacities and capabilities.

Scope of the Report

The "Antibody Contract Manufacturing Market, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities and location of these facilities, type of antibody manufactured (monoclonal antibodies, bispecific antibodies and polyclonal antibodies), type of expression systems used (mammalian, microbial and others), fill / finish operations and affiliations to regulatory agencies. 
  • A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation).
  • A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.
  • An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013, based on several parameters, such as the year of agreement, type of partnership, project scale and focus therapeutic area.
  • An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October), taking into consideration parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), type of antibodies manufactured and location of manufacturing facility.
  • An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia). 
  • Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.  
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes. 
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry. 

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the antibody contract manufacturing market. Based on multiple parameters, such as projected growth of overall antibody-based products market, cost of goods sold and direct manufacturing costs, we have developed informed estimates on the financial evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of antibodies (monoclonal antibodies, bispecific antibodies and others), [B] company size (small, mid-sized and large / very large), [C] scale of operation (preclinical / clinical and commercial), [E] expression systems (mammalian, microbial and others), and [F] key geographical regions (North America, Europe, Asia). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Dietmar Katinger, Chief Executive Officer, Polymun Scientific 
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology   
  • Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the antibody contract manufacturing market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to antibodies, including a brief discussion on the historical evolution of this class of medical products. It highlights the different categories of antibodies, namely monoclonal antibodies, bispecific antibodies and polyclonal antibodies, their potential applications, and mechanisms of action (as therapeutic interventions). In addition, it includes information on the structure of an antibody and its isotypes. Further, the chapter features a brief overview of contract manufacturing and includes a detailed discussion on the need for outsourcing within the biopharmaceutical industry and its advantages.

Chapter 4 provides an overview of the antibody contract manufacturing landscape. It includes information on over 115 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, scale of operation, geographical location of the CMO, number of manufacturing facilities, as well as location of these facilities, type of antibody manufactured, types of expression systems being used, fill / finish operations and affiliations to regulatory agencies.

Chapter 5 features a company competitiveness analysis of key players engaged in this domain. The analysis compares companies on the basis of their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation). 

Chapter 6 features detailed profiles of industry players that offer contract manufacturing services at preclinical, clinical and commercial scale and have more than two manufacturing facilities. Each profile provides a brief overview of the company, its contract service offerings, manufacturing capabilities and facilities and an informed future outlook.

Chapter 7 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps and challenges involved in their respective manufacturing processes.

Chapter 8 presents a benchmark analysis, highlighting the capabilities of small, mid-sized and large companies in terms of their service portfolio. Further, the analysis allows companies to compare their existing capabilities within and beyond their respective (geography-based) peer groups, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.

Chapter 9 features an analysis of the various collaborations and partnerships that have been inked amongst players in the time period 2013-2019 (till October). It provides a brief description on the various types of partnership models (which include manufacturing agreements, process development and manufacturing agreements, licensing agreements, acquisitions, joint ventures, service alliances and others) that have been adopted by stakeholders in this domain. Further, it includes analyses based on year of agreement, type of partnership, project scale and focus therapeutic area. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 presents detailed analysis on the recent expansions that have taken place in the antibody contract manufacturing industry, since 2017. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances that we came across were analyzed based on various parameters, including year of expansion, type of expansion (capacity expansion, facility expansion, new facility), type of antibodies (monoclonal antibodies, bispecific antibodies and polyclonal antibodies) and geographical location of the facility.

Chapter 11 features an analysis of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia).

Chapter 12 features a detailed analysis of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.

Chapter 13 presents a detailed market forecast analysis, highlighting the likely growth of the antibody contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of antibodies (monoclonal antibodies, bispecific antibodies and others), [B] company size (small, mid-sized and large / very large), [C] scale of operation (preclinical / clinical and commercial), [E] expression systems (mammalian, microbial and others), and [F] key geographical regions (North America, Europe, Asia).

Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of antibody contract manufacturing market, under a SWOT framework.

Chapter 15 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the antibody CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of antibody CMOs.

Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Dietmar Katinger (Chief Executive Officer, Polymun Scientific), David C Cunningham (Director Corporate Development, Goodwin Biotechnology) and Claire Otjes (Assistant Marketing Manager, Batavia Biosciences).

Chapter 17 is an appendix that contains the list of companies that offer custom manufacturing services for different type of antibodies.

Chapter 18 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of an Antibody
3.3. Structure of an Antibody
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies

3.6. Types of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Bispecific Antibodies
3.6.3. Polyclonal Antibodies

3.7. Overview of Contract Manufacturing
3.8. Need for Outsourcing in the Biopharmaceutical Industry
3.9. Advantages of Outsourcing Manufacturing Services

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Antibody Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Location of Manufacturing Facilities
4.2.6. Analysis by Type of Antibodies Manufactured
4.2.7. Analysis by Expression Systems Used
4.2.8. Analysis by Fill / Finish Services Offered
4.2.9. Analysis by Regulatory Accreditations / Certifications

5. COMPANY COMPETITIVE ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Input Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
5.5. Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
5.6. Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. AGC Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Future Outlook

6.3. Aldevron
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Future Outlook

6.4. BioXcellence (Boehringer Ingelheim)
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Future Outlook

6.5. FUJIFILM Diosynth Biotechnologies
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Future Outlook

6.6. Lonza
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Future Outlook

6.7. Merck
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Manufacturing Facilities and Capabilities
6.7.4. Future Outlook

6.8. Novasep
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Manufacturing Facilities and Capabilities
6.8.4. Future Outlook

6.9. Samsung BioLogics
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Manufacturing Facilities and Capabilities
6.9.4. Future Outlook

6.10. Synthon
6.10.1. Company Overview
6.10.2. Service Portfolio
6.10.3. Manufacturing Facilities and Capabilities
6.10.4. Future Outlook

7. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES
7.1. Chapter Overview
7.2. Small Molecule Drugs and Biologics
7.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
7.2.2. Comparison of Key Specifications
7.2.3. Comparison of Manufacturing Processes
7.2.4. Comparison of Key Manufacturing-related Challenges

8. BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Region-wise Benchmarking
8.3.1. North America, Peer Group I
8.3.2. North America, Peer Group II
8.3.3. North America, Peer Group III
8.3.4. Europe, Peer Group IV
8.3.5. Europe, Peer Group V
8.3.6. Europe, Peer Group VI
8.3.7. Asia, Peer Group VII
8.3.8. Asia, Peer Group VIII

8.4. Concluding Remarks

9. PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnerships Models

9.3. Antibody Contract Manufacturing: List of Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Antibody
9.3.5. Analysis by Project Scale
9.3.6. Analysis by Focus Therapeutic Area

9.3.7. Most Active Players: Analysis by Number of Partnerships and Type of Partnership
9.3.8. Geographical Analysis
9.3.8.1. Continent-wise Distribution
9.3.8.2. Country-wise Distribution

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Antibody Contract Manufacturers: List of Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Type of Antibody
10.2.4. Analysis by Location of Manufacturing Facility
10.2.5. Analysis by Location of Manufacturing Facility and Type of Expansion
10.2.6. Analysis of Most Active Players by Number of Expansions
10.2.7. Geographical Analysis
10.2.7.1. Country-wise Distribution

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Antibody Contract Manufacturers: Installed Global Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Manufacturing Facility
11.4. Concluding Remarks

12. DEMAND ANALYSIS
12.1 Chapter Overview
12.2 Assumptions and Methodology
12.3 Antibody Contract Manufacturing Market: Overall Annual Demand
12.3.1. Analysis by Scale of Operation
12.3.2. Analysis by Geography

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Forecast Methodology

13.3. Overall Antibody Contract Manufacturing Market, 2020-2030
13.4. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody
13.5. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size
13.6. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
13.7. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used

13.8. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography
13.8.1. Antibody Contract Manufacturing Market in North America, 2020-2030
13.8.1.1. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies
13.8.1.2. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
13.8.1.3. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies

13.8.1.4. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.1.5. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations

13.8.1.6. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations
13.8.1.7. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations
13.8.1.8. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations

13.8.2. Antibody Contract Manufacturing Market in Europe, 2020-2030
13.8.2.1. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies
13.8.2.2. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
13.8.2.3. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies

13.8.2.4. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.2.5. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations

13.8.2.6. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations
13.8.2.7. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations
13.8.2.8. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations

13.8.3. Antibody Contract Manufacturing Market in Asia, 2020-2030
13.8.3.1. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies
13.8.3.2. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies
13.8.3.3. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies

13.8.3.4. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.3.5. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations

13.8.3.6. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations
13.8.3.7. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations
13.8.3.8. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations

14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Comparison of SWOT Factors
14.7. Concluding Remarks

15. FUTURE OF THE ANTIBODY CMO MARKET
15.1. Chapter Overview
15.2. Outsourcing Activity Anticipated to Witness Significant Growth
15.3. Shift from One-time Contractual Engagements to Strategic Partnerships
15.4. Adoption of New and Innovative Technologies
15.5. Concluding Remarks

16. INTERVIEW TRANSCRIPTS
16.1. Chapter Overview
16.2. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
16.3. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
16.4. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biopharma
16.5. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

17. APPENDIX 1: LIST OF ANTIBODY CUSTOM MANUFACTURERS

18. APPENDIX 2: TABULATED DATA

19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figuers

Figure 3.1 Historical Milestones Related to the Discovery of Antibodies
Figure 3.2 Structure of an Antibody
Figure 3.3 Mechanism of Action of Antibodies
Figure 3.4 Monoclonal Antibody Production
Figure 3.5 Symmetric and Asymmetric Bispecific Antibodies
Figure 3.6 Mechanism of Action of Bispecific Antibodies
Figure 3.7 Polyclonal Antibody Production
Figure 3.8 Applications of Polyclonal Antibodies
Figure 3.9 Types of Third Party Service Providers
Figure 4.1 Antibody Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Antibody Contract Manufacturers: Distribution by Company Size
Figure 4.3 Antibody Contract Manufacturers: Distribution by Scale of Operation
Figure 4.4 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 4.5 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 4.6 Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 4.7 Antibody Contract Manufacturers: Distribution by Type of Antibodies Manufactured
Figure 4.8 Antibody Contract Manufacturers: Distribution by Expression Systems Used
Figure 4.9 Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
Figure 4.10 Antibody Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
Figure 5.1 Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
Figure 5.2 Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
Figure 5.3 Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia
Figure 6.1 AGC Biologics: Service Portfolio
Figure 6.2 Aldevron: Service Portfolio
Figure 6.3 BioXcellence (Boehringer Ingelheim): Service Portfolio
Figure 6.4 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 6.5 Lonza: Service Portfolio
Figure 6.6 Merck: Service Portfolio
Figure 6.7 Novasep: Service Portfolio
Figure 6.8 Samsung BioLogics: Service Portfolio
Figure 6.9 Synthon: Service Portfolio
Figure 7.1 Small Molecules and Biologics: Historical Trend of FDA Approval, 2010-2019 (till August)
Figure 7.2 Comparison of Key Characteristics of Small Molecules and Biologics
Figure 7.3 Comparison of Manufacturing Processes of Small Molecules and Biologics
Figure 8.1 Benchmark Analysis: Distribution by Region and Company Size
Figure 8.2 Benchmark Analysis: North America, Peer Group I
Figure 8.3 Benchmark Analysis: North America, Peer Group II
Figure 8.4 Benchmark Analysis: North America, Peer Group III
Figure 8.5 Benchmark Analysis: Europe, Peer Group IV
Figure 8.6 Benchmark Analysis: Europe, Peer Group V
Figure 8.7 Benchmark Analysis: Europe, Peer Group VI
Figure 8.8 Benchmark Analysis: Asia, Peer Group VII
Figure 8.9 Benchmark Analysis: Asia, Peer Group VIII
Figure 8.10 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups
Figure 9.1 Partnerships: Distribution by Year of Partnership
Figure 9.2 Partnerships: Distribution by Type of Partnership
Figure 9.3 Partnerships: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships: Distribution by Type of Antibody
Figure 9.5 Partnerships: Distribution by Project Scale
Figure 9.6 Partnerships: Distribution by Focus Therapeutic Area
Figure 9.7 Partnerships: Most Active Players
Figure 9.8 Partnerships: Country-wise Distribution
Figure 9.9 Partnerships: Continent-wise Distribution
Figure 10.1 Recent Expansions: Distribution by Year of Expansion
Figure 10.2 Recent Expansions: Distribution by Type of Expansion
Figure 10.3 Recent Expansions: Distribution by Type of Antibody
Figure 10.4 Recent Expansions: Distribution by Type of Antibody and Expansion
Figure 10.5 Recent Expansions: Distribution by Location of Facility (Region-wise)
Figure 10.6 Recent Expansions: Distribution by Location of Facility (Country-wise)
Figure 10.7 Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
Figure 10.8 Recent Expansions: Most Active Players
Figure 10.9 Recent Expansions: Distribution by Local and International Expansions
Figure 11.1. Antibody Contract Manufacturing: Installed Global Capacity
Figure 11.2. Antibody Contract Manufacturing Capacity: Distribution by Company Size
Figure 11.3. Antibody Contract Manufacturing Capacity: Distribution by Scale of Operation
Figure 11.4. Antibody Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Figure 12.1 Demand Analysis: Annual Demand for Antibodies
Figure 12.2 Demand Analysis: Annual Demand for Clinical Scale Operations
Figure 12.3 Demand Analysis: Annual Demand for Commercial Scale Operations
Figure 12.4 Demand Analysis: Annual Demand in North America
Figure 12.5 Demand Analysis: Annual Demand in Europe
Figure 12.6 Demand Analysis: Annual Demand in Asia
Figure 13.1 Overall Antibody Contract Manufacturing Market, 2020-2030
Figure 13.2 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody (USD Billion)
Figure 13.3 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
Figure 13.4 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.5 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used (USD Billion)
Figure 13.6 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
Figure 13.7 Antibody Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
Figure 13.8 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
Figure 13.9 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 13.10 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 13.11 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Figure 13.12 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Figure 13.13 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 13.14 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 13.15 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 13.16 Antibody Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
Figure 13.17 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
Figure 13.18 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 13.19 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 13.20 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Figure 13.21 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Figure 13.22 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 13.23 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 13.24 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 13.25 Antibody Contract Manufacturing Market in Asia, 2020-2030 (USD Billion)
Figure 13.26 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies (USD Billion)
Figure 13.27 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 13.28 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 13.29 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Figure 13.30 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Figure 13.31 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 13.32 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 13.33 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 14.1 Antibody Contract Manufacturing: SWOT Analysis
Figure 14.2 Comparison of SWOT Factors: Harvey Ball Analysis

List Of Table

Table 3.1 Key Features of Antibody Isotypes
Table 3.2 Mechanism of Action of Therapeutic Antibodies against Important Target Classes
Table 3.3 List of Approved Monoclonal Antibodies
Table 3.4 Differences between Monoclonal and Polyclonal Antibodies
Table 4.1 List of Antibody Contract Manufacturers
Table 4.2 Antibody Contract Manufacturers: Information on Type of Antibodies Manufactured
Table 4.3 Antibody Contract Manufacturers: Information on Scale of Operation
Table 4.4 Antibody Contract Manufacturers: Information on Expression Systems Used
Table 4.5 Antibody Contract Manufacturers: Information on Fill / Finish Services Offered
Table 4.6 Antibody Contract Manufacturers: Information on Regulatory Accreditations / Certifications
Table 6.1 AGC Biologics: Company Overview
Table 6.2 AGC Biologics: Overview of Manufacturing Capabilities
Table 6.3 AGC Biologics: Future Outlook
Table 6.4 Aldevron: Company Overview
Table 6.5 Aldevron: Overview of Manufacturing Capabilities
Table 6.6 Aldevron: Future Outlook
Table 6.7 BioXcellence (Boehringer Ingelheim): Company Overview
Table 6.8 BioXcellence (Boehringer Ingelheim): Overview of Manufacturing Capabilities
Table 6.9 BioXcellence (Boehringer Ingelheim): Future Outlook
Table 6.10 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 6.11 FUJIFILM Diosynth Biotechnologies: Overview of Manufacturing Capabilities
Table 6.12 FUJIFILM Diosynth Biotechnologies: Future Outlook
Table 6.13 Lonza: Company Overview
Table 6.14 Lonza: Overview of Manufacturing Capabilities
Table 6.15 Lonza: Future Outlook
Table 6.16 Merck: Company Overview
Table 6.17 Merck: Overview of Manufacturing Capabilities
Table 6.18 Merck: Future Outlook
Table 6.19 Novasep: Company Overview
Table 6.20 Novasep: Overview of Manufacturing Capabilities
Table 6.21 Novasep: Future Outlook
Table 6.22 Samsung BioLogics: Company Overview
Table 6.23 Samsung BioLogics: Overview of Manufacturing Capabilities
Table 6.24 Samsung BioLogics: Future Outlook
Table 6.25 Synthon: Company Overview
Table 6.26 Synthon: Overview of Manufacturing Capabilities
Table 6.27 Synthon: Future Outlook
Table 7.1 Comparison of Strengths and Weaknesses of Small Molecules and Biologics
Table 7.2 Comparison of Development Characteristics of Small Molecules and Biologics
Table 8.1 Benchmark Analysis: Peer Groups
Table 9.1 Antibody Contract Manufacturing: List of Partnerships, 2013-2019
Table 9.2 Antibody Contract Manufacturing Partnerships: Information on Type of Antibodies, Project Scale and Therapeutic Area
Table 10.1 Antibody Contract Manufacturing: List of Expansions, 2017-2019
Table 10.2 Antibody Contract Manufacturing Expansions: Information on Type of Antibodies
Table 14.1 Patent Approval Information of Best-selling Biologics
Table 17.1 Antibody Contract Manufacturers: Distribution by Year of Establishment
Table 17.2 Antibody Contract Manufacturers: Distribution by Company Size
Table 17.3 Antibody Contract Manufacturers: Distribution by Scale of Operation
Table 17.4 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Table 17.5 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 17.6 Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Table 17.7 Antibody Contract Manufacturers: Distribution by Type of Antibodies Manufactured
Table 17.8 Antibody Contract Manufacturers: Distribution by Expression Systems Used
Table 17.9 Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
Table 17.10 Antibody Contract Manufacturers: Distribution by Regulatory Accreditations /
Table 17.11 Small Molecules and Biologics: Historical Trend of FDA Approval, 2010-2019 (till August)
Table 17.12 Partnerships: Distribution by Year of Partnership
Table 17.13 Partnerships: Distribution by Type of Partnership
Table 17.14 Partnerships: Distribution by Year and Type of Partnership
Table 17.15 Partnerships: Distribution by Type of Antibody
Table 17.16 Partnerships: Distribution by Project Scale
Table 17.17 Partnerships: Distribution by Focus Therapeutic Area
Table 17.18 Partnerships: Most Active Players
Table 17.19 Partnerships: Country-wise Distribution
Table 17.20 Recent Expansions: Distribution by Year of Expansion
Table 17.21 Recent Expansions: Distribution by Type of Expansion
Table 17.22 Recent Expansions: Distribution by Type of Antibody
Table 17.23 Recent Expansions: Distribution by Type of Antibody and Expansion
Table 17.24 Recent Expansions: Distribution by Location of Facility (Region-wise)
Table 17.25 Recent Expansions: Distribution by Location of Facility (Country-wise)
Table 17.26 Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
Table 17.27 Recent Expansions: Most Active Players
Table 17.28 Recent Expansions: Distribution by Local and International Expansions
Table 17.29 Antibody Contract Manufacturing: Installed Global Capacity
Table 17.30 Antibody Contract Manufacturing Capacity: Distribution by Company Size
Table 17.31 Antibody Contract Manufacturing Capacity: Distribution by Scale of Operation
Table 17.32 Antibody Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Table 17.33 Demand Analysis: Annual Demand for Antibodies
Table 17.34 Demand Analysis: Annual Demand for Clinical Scale Operations
Table 17.35 Demand Analysis: Annual Demand for Commercial Scale Operations
Table 17.36 Demand Analysis: Annual Demand in North America
Table 17.37 Demand Analysis: Annual Demand in Europe
Table 17.38 Demand Analysis: Annual Demand in Asia
Table 17.39 Overall Antibody Contract Manufacturing Market, 2020-2030
Table 17.40 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody (USD Billion)
Table 17.41 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
Table 17.42 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Table 17.43 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used (USD Billion)
Table 17.44 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
Table 17.45 Antibody Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
Table 17.46 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
Table 17.47 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 17.48 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 17.49 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Table 17.50 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Table 17.51 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Table 17.52 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Table 17.53 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Table 17.54 Antibody Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
Table 17.55 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
Table 17.56 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 17.57 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 17.58 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Table 17.59 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Table 17.60 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Table 17.61 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Table 17.62 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Table 17.63 Antibody Contract Manufacturing Market in Asia, 2020-2030 (USD Billion)
Table 17.64 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies (USD Billion)
Table 17.65 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 17.66 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 17.67 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Table 17.68 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Table 17.69 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Table 17.70 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Table 17.71 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations (USD Billion)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. AbbVie Contract Manufacturing
  2. Abcuro
  3. Abdi Ibrahim
  4. A-Bio Pharma
  5. ABL
  6. ABL Bio
  7. Absolute Antibody
  8. Abzena
  9. AC Immune
  10. Acticor Biotech 
  11. Actinium Pharmaceuticals
  12. Adagene
  13. Affinita Biotech
  14. Affinity Life Sciences
  15. AGC Biologics
  16. Ajinomoto Althea
  17. Alcami
  18. Aldevron
  19. Alethia Biotherapeutics
  20. Allele Biotechnology & Pharmaceuticals
  21. Alligator Bioscience
  22. Alvotech
  23. Annular Biotech
  24. Antibodies Incorporated
  25. Antibody Production Services (division of Life Science Group)
  26. Arabio
  27. Arcus Biosciences
  28. argenx
  29. ASKA Biotech
  30. ASLAN Pharmaceuticals
  31. AURA Biotechnologies 
  32. AutekBio
  33. Avid Bioservices
  34. Avioq
  35. Axcellerate Pharma
  36. Batavia Biosciences
  37. Baxter BioPharma Solutions
  38. Bayer
  39. Baylor Scott & White Research Institute
  40. BeiGene
  41. Bharat Serums and Vaccine
  42. BIBITEC
  43. BINEX
  44. BioInvent International
  45. BioLineRx
  46. Biomay
  47. Biomedical Advanced Research and Development Authority (BARDA)
  48. BiosanaPharma
  49. Biosynergy EUROPE
  50. BioTechnique
  51. Biovian
  52. BioVolutions
  53. BioXcellence (Boehringer Ingelheim)
  54. BJ Bioscience
  55. Brii Biosciences
  56. Bristol-Myers Squibb
  57. Bruker
  58. Calypso Biotech
  59. CANbridge
  60. Capralogics
  61. Catalent
  62. Catalent Biologics
  63. Cell Culture Company
  64. Cell Essentials
  65. Celonic
  66. Center of iPS Cell Research and Application, Kyoto University
  67. Cerbios-Pharma
  68. Changchun High & New Technology Industry
  69. ChemPartner
  70. Chiome Bioscience
  71. CinnaGen 
  72. Citryll
  73. CMAB Biopharma
  74. CMC Biologics
  75. Cobra Biologics
  76. Compugen
  77. Cook Pharmica
  78. Creative Biolabs
  79. CytoDyn
  80. Cytovance® Biologics
  81. DaTaMabs
  82. Diatec Monoclonals
  83. DM Bio
  84. Dyax 
  85. Effimune
  86. EirGenix
  87. Emergent BioSolutions
  88. Enzene Biosciences
  89. Etinpro
  90. EuBiologics
  91. Eurofins CDMO
  92. Eurogentec
  93. exonbio
  94. FairJourney Biologics
  95. Faron Pharmaceuticals
  96. Forty Seven
  97. F-star
  98. FUJIFILM Diosynth Biotechnologies
  99. GlaxoSmithKline
  100. Glenmark
  101. Goodwin Biotechnology
  102. GTP Technology
  103. HALIX 
  104. Harbour BioMed
  105. Hong Kong Institute of Biotechnology
  106. Horizon Pharma
  107. IBC Generium
  108. IDT Biologika
  109. I-Mab Biopharma
  110. Immune Pharmaceuticals
  111. Inno Biologics 
  112. InVivo Biotech
  113. JHL Biotech
  114. JSR
  115. KBI Biopharma
  116. Kemwell Biopharma
  117. KUBio (a manufacturing unit of GE Healthcare)
  118. LakePharma
  119. LAMPIRE Biological Laboratories
  120. Laureate Biopharmaceutical Services
  121. LFB Biomanufacturing
  122. Lipum
  123. Lonza
  124. Lupin
  125. Mabion
  126. MabPlex
  127. MAbSilico
  128. Mab-Venture Biopharma
  129. MacroGenics
  130. Maine Biotechnology Services
  131. MassBiologics
  132. Medicago
  133. MedImmune
  134. Medix Biochemica
  135. Menarini Biotech
  136. Merck
  137. Meridian Life Science
  138. Merus
  139. Mologic
  140. MorphoSys 
  141. Mycenax Biotech
  142. Nitto Avecia Pharma Services
  143. Northway Biotechpharma
  144. Novasep
  145. NovoCodex Biopharmaceuticals
  146. Omeros
  147. OncoQuest
  148. OncoSynergy
  149. OncoVent
  150. OsoBio
  151. Pall
  152. Pamlico Biopharma
  153. Paragon Bioservices (a unit of Catalent Biologics)
  154. Particle Sciences (a Lubrizol Company)
  155. Pharmedartis
  156. Pierre Fabre
  157. Pionyr Immunotherapeutics
  158. Piramal Pharma Solutions
  159. PMI BioPharma Solutions
  160. Polymun Scientific
  161. Powerway Biotech
  162. Praxis Pharmaceutical
  163. Precision Biologics 
  164. Premas Biotech
  165. Prestige BioPharma
  166. ProBioGen
  167. PX'Therapeutics
  168. Radimmune Therapeutics
  169. ReliaTech
  170. Rentschler Biopharma
  171. Richter-Helm BioLogics
  172. River Vision Development
  173. RuiYi
  174. Samsung BioLogics
  175. Sandoz (a Novartis division)
  176. Sanofi
  177. SDIX
  178. Selexis
  179. Selexys Pharmaceuticals (acquired by Novartis)
  180. Siam Bioscience
  181. Siegfried
  182. Sun Pharmaceutical
  183. Surface Oncology 
  184. Suzhou Kintor Pharmaceuticals
  185. Symbiosis Pharmaceutical Services
  186. Symphogen
  187. Syngene (a subsidiary of Biocon)
  188. Synthelis
  189. Synthon
  190. Takara Bio
  191. The Native Antigen
  192. Therapure Biopharma (Therapure Biomanufacturing)
  193. Thermo Fisher Scientific
  194. Tizona Therapeutics
  195. Tmunity Therapeutics
  196. Toyobo Biologics 
  197. Translational Sciences
  198. Trellis Bioscience
  199. University College London
  200. University of Toyama 
  201. Vibalogics
  202. Vivoryon Therapeutics
  203. Wacker Biotech 
  204. Waisman Biomanufacturing
  205. WuXi AppTec
  206. WuXi Biologics
  207. Xpress Biologics
  208. Zymeworks

Segmentation

The USD 13.8 billion (by 2030) financial opportunity within the antibody contract manufacturing market has been analyzed across the following segments:

  • Type of Antibodies
    • Monoclonal Antibodies 
    • Bispecific Antibodies
    • Others
  • Company Size
    • Small 
    • Mid-sized 
    • Large / Very Large 
  • Scale of Operation
    • Clinical
    • Commercial
  • Type of expression system used
    • Mammalian
    • Microbial and others
  • Key geographical regions 
    • North America
    • Europe
    • Asia

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com